A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation

References

• Fridell JA, Niederhaus S, Curry M, et al. The survival advantage of pancreas after kidney transplant. Am J Transplant. 2019;19(3):823–830. doi: 10.1111/ajt.15106
   PubMed Web of Science ®Google Scholar
• Sollinger HW, Odorico JS, Becker YT, et al. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg. 2009;250(4):618–630. doi: 10.1097/SLA.0b013e3181b76d2b
   PubMed Web of Science ®Google Scholar
• Jenssen T, Hartmann A, Birkeland KI. Long-term diabetes complications after pancreas transplantation. Curr Opin Organ Transplant. 2017;22(4):382–388. doi: 10.1097/MOT.0000000000000436
   PubMed Web of Science ®Google Scholar
• Reine TM, Kolseth IB, Meen AJ, et al. Effects of restoring normoglycemia in type 1 diabetes on inflammatory profile and renal extracellular matrix structure after simultaneous pancreas and kidney transplantation. Diabet Res Clin Pract. 2015;107(1):46–53. doi: 10.1016/j.diabres.2014.10.006
   PubMed Web of Science ®Google Scholar
• Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69–75. doi: 10.1056/NEJM199807093390202
   PubMed Web of Science ®Google Scholar
• Kandaswamy R, Stock PG, Miller J, et al. OPTN/SRTR 2019 annual data report: pancreas. Am J Transplant. 2021;21 Suppl 2:138–207. doi: 10.1111/ajt.16496
   PubMed Web of Science ®Google Scholar
• Kandaswamy R, Stock PG, Miller J, et al. OPTN/SRTR 2020 annual data report: pancreas. Am J Transplant. 2022;22 Suppl 2:137–203. doi: 10.1111/ajt.16979
   PubMed Web of Science ®Google Scholar
• Anderson PT, Aquil S, McLean K, et al. First Canadian experience with donation after cardiac death simultaneous pancreas and kidney transplants. Can J Surg. 2017;60(5):323–328. doi: 10.1503/cjs.011315
   PubMed Web of Science ®Google Scholar
• Kandaswamy R, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2013 annual data report: pancreas. Am J Transplant. 2015;15(Suppl 2):1–20. doi: 10.1111/ajt.13196
   PubMed Web of Science ®Google Scholar
• Finger EB, Radosevich DM, Dunn TB, et al. A composite risk model for predicting technical failure in pancreas transplantation. Am J Transplant. 2013;13(7):1840–1849. doi: 10.1111/ajt.12269
   PubMed Web of Science ®Google Scholar
• Siskind E, Maloney C, Jayaschandaran V, et al. Pancreatic retransplantation is associated with poor allograft survival: an update of the united network for organ sharing database. Pancreas. 2015;44(5):769–772. doi: 10.1097/MPA.0000000000000330
   PubMed Web of Science ®Google Scholar
• Perosa M, Sergi F, Noujaim H. Outcomes after pancreas retransplantation: is the juice worth the squeeze? Curr Opin Organ Transplant. 2018;23(4):461–466. doi: 10.1097/MOT.0000000000000554
   PubMed Web of Science ®Google Scholar
• Kopp W, van Meel, van MM H, et al. Center volume is associated with outcome after pancreas transplantation within the eurotransplant region. Transplantation. 2017;101(6):1247–1253. doi: 10.1097/TP.0000000000001308
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts—updated Banff grading schema. Am J Transplant. 2011;11(9):1792–1802. doi: 10.1111/j.1600-6143.2011.03670.x
   PubMed Web of Science ®Google Scholar
• Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol. 2012;8(12):1531–1548. doi: 10.1517/17425255.2012.724058
   PubMed Web of Science ®Google Scholar
• Cerise A, Shaker T, LeNguyen P, et al. Outcomes of primary simultaneous pancreas-kidney transplants by induction agent in the United States. Transplant Direct. 2022;8(12):e1412. doi: 10.1097/TXD.0000000000001412
   PubMed Web of Science ®Google Scholar
• Cantarovich D, Kervella D, Karam G, et al. Tacrolimus- versus sirolimus-based immunosuppression after simultaneous pancreas and kidney transplantation: 5-year results of a randomized trial. Am J Transplant. 2020;20(6):1679–1690. doi: 10.1111/ajt.15809
   PubMed Web of Science ®Google Scholar
• Stock PG, Mannon RB, Armstrong B, et al. Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: results of a prospective, randomized clinical trial. Am J Transplant. 2020;20(6):1668–1678. doi: 10.1111/ajt.15817
   PubMed Web of Science ®Google Scholar
• Girman P, Lipar K, Kocik M, et al. Sirolimus vs mycophenolate mofetil (MMF) in primary combined pancreas and kidney transplantation. Results of a long-term prospective randomized study. Am J Transplant. 2020;20(3):779–787. doi: 10.1111/ajt.15622
   PubMed Web of Science ®Google Scholar
• Siskind EJ, Liu C, Collins DT, et al. Use of mammalian target of rapamycin inhibitors for pancreas transplant immunosuppression is associated with improved allograft survival and improved early patient survival. Pancreas. 2019;48(5):644–651. doi: 10.1097/MPA.0000000000001322
   PubMed Web of Science ®Google Scholar
• Bosmuller C, Messner F, Margreiter C, et al. Good results with individually adapted long-term immunosuppression following alemtuzumab versus ATG induction therapy in combined kidney-pancreas transplantation: a single-center report. Ann Transplant. 2019;24:52–56. doi: 10.12659/AOT.911712
   PubMed Web of Science ®Google Scholar
• Li J, Koch M, Kramer K, et al. Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation. Transpl Immunol. 2018;50:26–33. doi: 10.1016/j.trim.2018.06.001
   PubMed Web of Science ®Google Scholar
• Fridell JA, Mangus RS, Chen JM, et al. Steroid-free three-drug maintenance regimen for pancreas transplant alone: comparison of induction with rabbit antithymocyte globulin +/− rituximab. Am J Transplant. 2018;18(12):3000–3006. doi: 10.1111/ajt.14921
   PubMed Web of Science ®Google Scholar
• Bank JR, Heidt S, Moes DJ, et al. Alemtuzumab induction and delayed acute rejection in steroid-free simultaneous pancreas-kidney transplant recipients. Transplant Direct. 2017;3(1):e124. doi: 10.1097/TXD.0000000000000634
   PubMed Web of Science ®Google Scholar
• Fernandez-Burgos I, Montiel Casado MC, Perez-Daga JA, et al. Induction therapy in simultaneous pancreas-kidney transplantation: thymoglobulin versus basiliximab. Transplant Proc. 2015;47(1):120–122. doi: 10.1016/j.transproceed.2014.12.003
   PubMed Web of Science ®Google Scholar
• Stratta RJ, Rogers J, Orlando G, et al. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin. Expert Opin Biol Ther. 2014;14(12):1723–1730. doi: 10.1517/14712598.2014.953049
   PubMed Web of Science ®Google Scholar
• Sageshima J, Ciancio G, Chen L, et al. Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation. Clin Transplant. 2014;28(7):797–801. doi: 10.1111/ctr.12381
   PubMed Web of Science ®Google Scholar
• Zachariah M, Gregg A, Schold J, et al. Alemtuzumab induction in simultaneous pancreas and kidney transplantation. Clin Transplant. 2013;27:693–700. doi: 10.1111/ctr.12199
   PubMed Web of Science ®Google Scholar
• Ciancio G, Sageshima J, Chen L, et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. Am J Transplant. 2012;12(12):3363–3376. doi: 10.1111/j.1600-6143.2012.04235.x
   PubMed Web of Science ®Google Scholar
• Bosmuller C, Ollinger R, Sieb M, et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. Ann Transplant. 2012;17(4):45–51. doi: 10.12659/AOT.883693
   PubMed Web of Science ®Google Scholar
• Amorese G, Lombardo C, Tudisco A, et al. Induction and immunosuppressive management of pancreas transplant recipients. Curr Pharm Des. 2020;26(28):3425–3439. doi: 10.2174/1381612826666200430111620
   PubMed Web of Science ®Google Scholar
• Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug–drug interactions. Expert Opin Drug Metab Toxicol. 2014;10(11):1585–1605. doi: 10.1517/17425255.2014.964205
   PubMed Web of Science ®Google Scholar
• Fernandes-Silva G, Ivani de P M, EB R. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2017;13:367–385.
   PubMed Web of Science ®Google Scholar
• de Lucena DD, Rangel ÉB, De Lucena EB. Glucocorticoids use in kidney transplant setting. Expert Opin Drug Metab Toxicol. 2018;14(10):1023–1041. doi: 10.1080/17425255.2018.1530214
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019;103(9):1953–1963. doi: 10.1097/TP.0000000000002626
   PubMed Web of Science ®Google Scholar
• Chakkera HA, Weil EJ, Pham PT, et al. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36(5):1406–1412. doi: 10.2337/dc12-2067
   PubMed Web of Science ®Google Scholar
• Neidlinger N, Singh N, Klein C, et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant. 2010;10(2):398–406. doi: 10.1111/j.1600-6143.2009.02935.x
   PubMed Web of Science ®Google Scholar
• Knight RJ, Islam AK, Pham C, et al. Weight gain after simultaneous kidney and pancreas transplantation. Transplantation. 2020;104(3):632–639. doi: 10.1097/TP.0000000000002862
   PubMed Web of Science ®Google Scholar
• de Lucena DD, de Sa JR, Medina-Pestana JO, et al. Modifiable variables are major risk factors for posttransplant diabetes mellitus in a time-dependent manner in kidney transplant: an observational cohort study. J Diabetes Res. 2020;2020:1938703. doi: 10.1155/2020/1938703
   PubMed Web of Science ®Google Scholar
• Porrini E, Delgado P, Alvarez A, et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant. 2008;23(4):1436–1441. doi: 10.1093/ndt/gfm762
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodriguez AE, Porrini E, Torres A. Beta-cell dysfunction induced by tacrolimus: a way to explain type 2 diabetes? Int J Mol Sci. 2021;22(19):10311. doi: 10.3390/ijms221910311
   PubMed Web of Science ®Google Scholar
• Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes. 2013;62(8):2674–2682. doi: 10.2337/db13-0106
   PubMed Web of Science ®Google Scholar
• Lim SW, Jin L, Luo K, et al. Ginseng extract reduces tacrolimus-induced oxidative stress by modulating autophagy in pancreatic beta cells. Lab Invest. 2017;97(11):1271–1281. doi: 10.1038/labinvest.2017.75
   PubMed Web of Science ®Google Scholar
• Lombardi A, Trimarco B, Iaccarino G, et al. Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure. Cell Commun Signal. 2017;15(1):47. doi: 10.1186/s12964-017-0203-0
   PubMedGoogle Scholar
• Namvaran F, Sharifi A, Namvaran MM, et al. The effect of tacrolimus on reactive oxygen species and total antioxidant status in pancreatic beta cell line. Exp Clin Transplant. 2015;13(6):510–515. doi: 10.6002/ect.2014.0028
   PubMed Web of Science ®Google Scholar
• Tong L, Li W, Zhang Y, et al. Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway. Mol Med Rep. 2021;24(3). doi: 10.3892/mmr.2021.12297
   Web of Science ®Google Scholar
• Jin J, Jin L, Luo K, et al. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant. 2017;17(10):2601–2616. doi: 10.1111/ajt.14316
   PubMed Web of Science ®Google Scholar
• Constantinescu AA, Abbas M, Kassem M, et al. Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells. Mol Cell Biochem. 2016;418(1–2):91–102. doi: 10.1007/s11010-016-2736-8
   PubMed Web of Science ®Google Scholar
• Jin J, Lim SW, Jin L, et al. Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats. Korean J Intern Med. 2017;32(2):314–322. doi: 10.3904/kjim.2015.394
   PubMed Web of Science ®Google Scholar
• Luo K, Yu JH, Quan Y, et al. Therapeutic potential of coenzyme Q(10) in mitochondrial dysfunction during tacrolimus-induced beta cell injury. Sci Rep. 2019;9(1):7995. doi: 10.1038/s41598-019-44475-x
   PubMedGoogle Scholar
• Sun IO, Jin L, Jin J, et al. The effects of addition of coenzyme Q10 to metformin on sirolimus-induced diabetes mellitus. Korean J Intern Med. 2019;34(2):365–374. doi: 10.3904/kjim.2017.004
   PubMed Web of Science ®Google Scholar
• Tan S, Song L, Wang M, et al. ARF influences diabetes through promoting the proliferation and malignant development of β cells. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S702–S706. doi: 10.1080/21691401.2018.1505750
   PubMed Web of Science ®Google Scholar
• Speckmann T, Sabatini PV, Nian C, et al. Npas4 transcription factor expression is regulated by calcium signaling pathways and prevents tacrolimus-induced cytotoxicity in pancreatic beta cells. J Biol Chem. 2016;291(6):2682–2695. doi: 10.1074/jbc.M115.704098
   PubMed Web of Science ®Google Scholar
• Trinanes J, ten Dijke, ten DP N, et al. Tacrolimus-induced BMP/SMAD signaling associates with metabolic stress–activated FOXO1 to trigger β-cell failure. Diabetes. 2020;69(2):193–204. doi: 10.2337/db19-0828
   PubMed Web of Science ®Google Scholar
• Ozbay LA, Smidt K, Mortensen DM, et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol. 2011;162(1):136–146. doi: 10.1111/j.1476-5381.2010.01018.x
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodriguez AE, Trinanes J, Velazquez-Garcia S, et al. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. Am J Transplant. 2013;13(7):1665–1675. doi: 10.1111/ajt.12236
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodriguez AE, Trinanes J, Porrini E, et al. Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus. Nefrología (English Edition). 2015;35(3):264–272. doi: 10.1016/j.nefroe.2015.06.006
   PubMed Web of Science ®Google Scholar
• Trinanes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, et al. Deciphering tacrolimus-induced toxicity in pancreatic β cells. Am J Transplant. 2017;17(11):2829–2840. doi: 10.1111/ajt.14323
   PubMed Web of Science ®Google Scholar
• Okamoto H, Hribal ML, Lin HV, et al. Role of the forkhead protein FoxO1 in cell compensation to insulin resistance. J Clin Invest. 2006;116(3):775–782. doi: 10.1172/JCI24967
   PubMed Web of Science ®Google Scholar
• Guo S, Dai C, Guo M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. J Clin Invest. 2013;123(8):3305–3316. doi: 10.1172/JCI65390
   PubMed Web of Science ®Google Scholar
• Li L, Zhao H, Chen B, et al. FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake. J Transl Med. 2019;17(1):418. doi: 10.1186/s12967-019-02170-5
   PubMed Web of Science ®Google Scholar
• Nordheim E, Birkeland KI, Asberg A, et al. Preserved insulin secretion and kidney function in recipients with functional pancreas grafts 1 year after transplantation: a single-center prospective observational study. Eur J Endocrinol. 2018;179(4):251–259. doi: 10.1530/EJE-18-0360
   PubMed Web of Science ®Google Scholar
• Bleskestad KB, Nordheim E, Lindahl JP, et al. Insulin secretion and action after pancreas transplantation. A retrospective single-center study. Scand J Clin Lab Invest. 2021;81(5):365–370. doi: 10.1080/00365513.2021.1926535
   PubMed Web of Science ®Google Scholar
• Rangel EB, Melaragno CS, Neves MD, et al. Family history of diabetes as a new determinant of insulin sensitivity and secretion in patients who have undergone a simultaneous pancreas-kidney transplant. Exp Clin Transplant. 2010;8(1):29–37.
   PubMed Web of Science ®Google Scholar
• Ko Y, Shin S, Mun S, et al. Lack of improvement in insulin sensitivity after pancreas transplantation in recipients with a high level of calcineurin inhibitors. Pancreas. 2021;50(4):587–594. doi: 10.1097/MPA.0000000000001800
   PubMed Web of Science ®Google Scholar
• Andacoglu OM, Himmler A, Geng X, et al. Comparison of glycemic control after pancreas transplantation for Type 1 and Type 2 diabetic recipients at a high volume center. Clin Transplant. 2019;33(8):e13656. doi: 10.1111/ctr.13656
   PubMed Web of Science ®Google Scholar
• Teutonico A, Schena PF, Di PS. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16(10):3128–3135. doi: 10.1681/ASN.2005050487
   PubMed Web of Science ®Google Scholar
• Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411–1418. doi: 10.1681/ASN.2007111202
   PubMed Web of Science ®Google Scholar
• Handisurya A, Kerscher C, Tura A, et al. Conversion from tacrolimus to cyclosporine a improves glucose tolerance in HCV-positive renal transplant recipients. PLoS One. 2016;11(1):e0145319. doi: 10.1371/journal.pone.0145319
   PubMed Web of Science ®Google Scholar
• de Fijter JW, Holdaas H, Oyen O, et al. Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial. Am J Transplant. 2017;17(7):1853–1867. doi: 10.1111/ajt.14186
   PubMed Web of Science ®Google Scholar
• Mark W, Hechenleitner P, Dietze O, et al. Duodenal histology for monitoring treatment of acute rejection in pancreaticoduodenal allografts in rats. Transplantation. 2002;73(2):198–203. doi: 10.1097/00007890-200201270-00008
   PubMed Web of Science ®Google Scholar
• Kramer BK, Albano L, Banas B, et al. Efficacy of prolonged- and immediate-release tacrolimus in kidney transplantation: a pooled analysis of two large, randomized, controlled trials. Transplant Proc. 2017;49(9):2040–2049. doi: 10.1016/j.transproceed.2017.07.011
   PubMed Web of Science ®Google Scholar
• Cattral M, Luke S, Knauer MJ, et al. Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients. Clin Transplant. 2018;32(2):e13180. doi: 10.1111/ctr.13180
   Web of Science ®Google Scholar
• Falconer SJ, Jansen C, Oniscu GC. Conversion from twice-daily to once-daily tacrolimus in simultaneous pancreas-kidney transplant patients. Transplant Proc. 2014;46(5):1458–1462. doi: 10.1016/j.transproceed.2013.12.056
   PubMed Web of Science ®Google Scholar
• Uchida J, Kuwabara N, Machida Y, et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. Transplant Proc. 2012;44(1):128–133. doi: 10.1016/j.transproceed.2011.11.005
   PubMed Web of Science ®Google Scholar
• Torabi J, Konicki A, Rocca JP, et al. The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients. Am J Surg. 2020;219(4):583–586. doi: 10.1016/j.amjsurg.2020.02.027
   PubMed Web of Science ®Google Scholar
• Kamar N, Cassuto E, Piotti G, et al. Pharmacokinetics of prolonged-release once-daily formulations of tacrolimus in de novo kidney transplant recipients: a randomized, parallel-group, open-label, multicenter study. Adv Ther. 2019;36(2):462–477. doi: 10.1007/s12325-018-0855-1
   PubMed Web of Science ®Google Scholar
• Ruangkanchanasetr P, Sanohdontree N, Supaporn T, et al. Beta cell function and insulin resistance after conversion from tacrolimus twice-daily to extended-release tacrolimus once-daily in stable renal transplant recipients. Ann Transplant. 2016;21:765–774. doi: 10.12659/AOT.900638
   PubMed Web of Science ®Google Scholar
• Zmijewska AA, Zmijewski JW, Becker Jr EJ, et al. Bioenergetic maladaptation and release of HMGB1 in calcineurin inhibitor-mediated nephrotoxicity. Am J Transplant. 2021;21(9):2964–2977. doi: 10.1111/ajt.16561
   PubMed Web of Science ®Google Scholar
• Lim SW, Shin YJ, Luo K, et al. Ginseng increases Klotho expression by FoxO3-mediated manganese superoxide dismutase in a mouse model of tacrolimus-induced renal injury. Aging. 2019;11(15):5548–5569. doi: 10.18632/aging.102137
   PubMedGoogle Scholar
• Jin J, Jin L, Lim SW, et al. Klotho deficiency aggravates tacrolimus-induced renal injury via the phosphatidylinositol 3-Kinase-Akt-forkhead box Protein O pathway. Am J Nephrol. 2016;43(5):357–365. doi: 10.1159/000446447
   PubMed Web of Science ®Google Scholar
• Franco ML, Beyerstedt S, Rangel EB. Klotho and mesenchymal stem cells: a review on cell and gene therapy for chronic kidney disease and acute kidney disease. Pharmaceutics. 2021;14(1):11. doi: 10.3390/pharmaceutics14010011
   PubMed Web of Science ®Google Scholar
• Lim SW, Shin YJ, Luo K, et al. Effect of Klotho on autophagy clearance in tacrolimus-induced renal injury. Faseb J. 2019;33(2):2694–2706. doi: 10.1096/fj.201800751R
   PubMed Web of Science ®Google Scholar
• Cao R, Li Y, Hu X, et al. Glycyrrhizic acid improves tacrolimus-induced renal injury by regulating autophagy. Faseb J. 2023;37(2):e22749. doi: 10.1096/fj.202201409RR
   PubMed Web of Science ®Google Scholar
• Ding J, Jin J, Na LY, et al. Exogenous pancreatic kininogenase protects against tacrolimus-induced renal injury by inhibiting PI3K/AKT signaling: The role of bradykinin receptors. Int Immunopharmacol. 2022;105:108547. doi: 10.1016/j.intimp.2022.108547
   PubMed Web of Science ®Google Scholar
• Claus M, Herro R, Wolf D, et al. The TWEAK/Fn14 pathway is required for calcineurin inhibitor toxicity of the kidneys. Am J Transplant. 2018;18(7):1636–1645. doi: 10.1111/ajt.14632
   PubMed Web of Science ®Google Scholar
• Gonzalez-Guerrero C, Ocana-Salceda C, Berzal S, et al. Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells. Toxicol Appl Pharmacol. 2013;272(3):825–841. doi: 10.1016/j.taap.2013.08.011
   PubMed Web of Science ®Google Scholar
• Deng S, Jin T, Zhang L, et al. Mechanism of tacrolimus-induced chronic renal fibrosis following transplantation is regulated by ox-LDL and its receptor, LOX-1. Mol Med Rep. 2016;14(5):4124–4134. doi: 10.3892/mmr.2016.5735
   PubMed Web of Science ®Google Scholar
• Yang XQ, Yu SY, Yu L, et al. Effects of tacrolimus on autophagy protein LC3 in puromycin-damaged mouse podocytes. J Int Med Res. 2020;48(12):300060520971422. doi: 10.1177/0300060520971422
   PubMed Web of Science ®Google Scholar
• Shen X, Jiang H, Ying M, et al. Calcineurin inhibitors cyclosporin a and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep. 2016;6(1):32087. doi: 10.1038/srep32087
   PubMedGoogle Scholar
• Zhang S, Wang H, Liu Y, et al. Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the NFATc1/TRPC6 pathway. J Cell Mol Med. 2020;24(17):9810–9824. doi: 10.1111/jcmm.15562
   PubMed Web of Science ®Google Scholar
• Shengyou Y, Li Y, Zhihong H, et al. Influence of tacrolimus on podocyte injury inducted by angiotensin II. J Renin Angiotensin Aldosterone Syst. 2015;16(2):260–266. doi: 10.1177/1470320314568520
   PubMed Web of Science ®Google Scholar
• Liao R, Liu Q, Zheng Z, et al. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One. 2015;10(7):e0132724. doi: 10.1371/journal.pone.0132724
   PubMed Web of Science ®Google Scholar
• Wu J, Zheng C, Wang X, et al. MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes. J Clin Invest. 2015;125(11):4091–4106. doi: 10.1172/JCI81061
   PubMed Web of Science ®Google Scholar
• Gao Y, Yang H, Wang Y, et al. Evaluation of the inhibitory effect of tacrolimus combined with mycophenolate mofetil on mesangial cell proliferation based on the cell cycle. Int J Mol Med. 2020;46:1582–1592. doi: 10.3892/ijmm.2020.4696
   PubMed Web of Science ®Google Scholar
• Karolin A, Escher G, Rudloff S, et al. Nephrotoxicity of calcineurin inhibitors in kidney epithelial cells is independent of NFAT signaling. Front Pharmacol. 2021;12:789080. doi: 10.3389/fphar.2021.789080
   PubMed Web of Science ®Google Scholar
• Dao M, Lecru L, Vandermeersch S, et al. The cannabinoid receptor 1 is involved in renal fibrosis during chronic allograft dysfunction: proof of concept. J Cell Mol Med. 2019;23(11):7279–7288. doi: 10.1111/jcmm.14570
   PubMed Web of Science ®Google Scholar
• Lazelle RA, McCully BH, Terker AS, et al. Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension. J Am Soc Nephrol. 2016;27(5):1456–1464. doi: 10.1681/ASN.2015040466
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang S, Fei L, et al. Tacrolimus causes hypertension by increasing vascular contractility via RhoA (Ras Homolog Family Member A)/ROCK (Rho-Associated Protein Kinase) pathway in mice. Hypertension. 2022;79(10):2228–2238. doi: 10.1161/HYPERTENSIONAHA.122.19189
   PubMed Web of Science ®Google Scholar
• Prokai A, Csohany R, Sziksz E, et al. Calcineurin-inhibition results in upregulation of local renin and subsequent vascular endothelial growth factor production in renal collecting ducts. Transplantation. 2016;100(2):325–333. doi: 10.1097/TP.0000000000000961
   PubMed Web of Science ®Google Scholar
• Liu L, Guo J, Pang XL, et al. Exploration of the mechanism of NORAD activation of TGF-β1/Smad3 through miR-136-5p and promotion of tacrolimus-induced renal fibrosis. Ren Fail. 2023;45(1):2147083. doi: 10.1080/0886022X.2022.2147083
   PubMed Web of Science ®Google Scholar
• Vandenbussche C, Van der Hauwaert C, Dewaeles E, et al. Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Arch Toxicol. 2018;92(4):1539–1550. doi: 10.1007/s00204-018-2158-3
   PubMed Web of Science ®Google Scholar
• Lang Y, Zhao Y, Zheng C, et al. MiR-30 family prevents Upar-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes. Cell Death Dis. 2019;10(6):401. doi: 10.1038/s41419-019-1625-y
   PubMedGoogle Scholar
• Kim JW, Nam SA, Seo E, et al. Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy. Korean J Intern Med. 2021;36(6):1420–1436. doi: 10.3904/kjim.2020.323
   PubMed Web of Science ®Google Scholar
• Hoff U, Markmann D, Thurn-Valassina D, et al. The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation. PLoS One. 2022;17(4):e0266319. doi: 10.1371/journal.pone.0266319
   PubMed Web of Science ®Google Scholar
• Gui Z, Suo C, Tao J, et al. Everolimus alleviates renal allograft interstitial fibrosis by inhibiting epithelial-to-mesenchymal transition not only via inducing autophagy but also via stabilizing IkappaB-alpha. Front Immunol. 2021;12:753412. doi: 10.3389/fimmu.2021.753412
   PubMed Web of Science ®Google Scholar
• Kurdian M, Herrero-Fresneda I, Lloberas N, et al. Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One. 2012;7(3):e32516. doi: 10.1371/journal.pone.0032516
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Masuda S, Nishihara K. Inui K. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem Pharmacol. 2010;79(1):67–76. doi: 10.1016/j.bcp.2009.07.015
   PubMed Web of Science ®Google Scholar
• Shigematsu T, Tajima S, Fu R, et al. The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats. Life Sci. 2022;288:120150. doi: 10.1016/j.lfs.2021.120150
   PubMed Web of Science ®Google Scholar
• Piao SG, Bae SK, Lim SW, et al. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction. Transplantation. 2012;93(4):383–389. doi: 10.1097/TP.0b013e3182421604
   PubMed Web of Science ®Google Scholar
• Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest. 2010;120(4):1084–1096. doi: 10.1172/JCI39492
   PubMed Web of Science ®Google Scholar
• Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121(6):2197–2209. doi: 10.1172/JCI44774
   PubMed Web of Science ®Google Scholar
• Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121(6):2181–2196. doi: 10.1172/JCI44771
   PubMed Web of Science ®Google Scholar
• Canaud G, Bienaime F, Viau A, et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med. 2013;19(10):1288–1296. doi: 10.1038/nm.3313
   PubMed Web of Science ®Google Scholar
• Naik MG, Heller KM, Arns W, et al. Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database. Clin Transplant. 2014;28(1):67–79. doi: 10.1111/ctr.12280
   PubMed Web of Science ®Google Scholar
• Kuwahara S, Hosojima M, Kaneko R, et al. Megalin-mediated tubuloglomerular alterations in high-fat diet–induced kidney disease. J Am Soc Nephrol. 2016;27(7):1996–2008. doi: 10.1681/ASN.2015020190
   PubMed Web of Science ®Google Scholar
• Yamahara K, Kume S, Koya D, et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol. 2013;24(11):1769–1781. doi: 10.1681/ASN.2012111080
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Takabatake Y, Takahashi A, et al. High-fat diet–induced lysosomal dysfunction and impaired autophagic flux contribute to lipotoxicity in the kidney. J Am Soc Nephrol. 2017;28(5):1534–1551. doi: 10.1681/ASN.2016070731
   PubMed Web of Science ®Google Scholar
• Nakamura J, Yamamoto T, Takabatake Y, et al. TFEB-mediated lysosomal exocytosis alleviates high-fat diet–induced lipotoxicity in the kidney. JCI Insight. 2023;8(4). doi: 10.1172/jci.insight.162498
   Web of Science ®Google Scholar
• Schelling JR. The contribution of lipotoxicity to diabetic kidney disease. Cells. 2022;11(20):3236. doi: 10.3390/cells11203236
   PubMed Web of Science ®Google Scholar
• Shin S, Jung CH, Choi JY, et al. Long-term effects of pancreas transplant alone on nephropathy in type 1 diabetic patients with optimal renal function. PLoS One. 2018;13(1):e0191421. doi: 10.1371/journal.pone.0191421
   PubMed Web of Science ®Google Scholar
• Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant. 2017;17(5):1358–1369. doi: 10.1111/ajt.14090
   PubMed Web of Science ®Google Scholar
• Pascual J, Berger SP, Witzke O, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29(7):1979–1991. doi: 10.1681/ASN.2018010009
   PubMed Web of Science ®Google Scholar
• Berger SP, Sommerer C, Witzke O, et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019;19(11):3018–3034. doi: 10.1111/ajt.15480
   PubMed Web of Science ®Google Scholar
• Marcella-Neto R, de Sa JR, Melaragno CS, et al. Late conversion to sirolimus or everolimus after pancreas transplant. Transplant Proc. 2020;52(5):1376–1379. doi: 10.1016/j.transproceed.2020.02.028
   PubMed Web of Science ®Google Scholar
• Infante B, Bellanti F, Correale M, et al. mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction. Aging. 2021;13(6):8026–8039. doi: 10.18632/aging.202863
   PubMedGoogle Scholar
• Aziz F, Jorgenson MR, Parajuli S, et al. Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant. Transpl Infect Dis. 2020;22(3):e13272. doi: 10.1111/tid.13272
   PubMed Web of Science ®Google Scholar
• Knight RJ, Graviss EA, Nguyen DT, et al. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-Mtor immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia. Clin Transplant. 2018;32(6):e13265. doi: 10.1111/ctr.13265
   PubMed Web of Science ®Google Scholar
• Shah AP, Chen JM, Fridell JA. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression. Clin Transplant. 2015;29(12):1221–1229. doi: 10.1111/ctr.12655
   PubMed Web of Science ®Google Scholar
• Axelrod D, Leventhal JR, Gallon LG, et al. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas–kidney transplant recipients. Am J Transplant. 2005;5(6):1423–1429. doi: 10.1111/j.1600-6143.2005.00855.x
   PubMed Web of Science ®Google Scholar
• Kaminski H, Marseres G, Yared N, et al. mTOR inhibitors prevent CMV infection through the restoration of functional αβ and γδ T cells in kidney transplantation. J Am Soc Nephrol. 2022;33(1):121–137. doi: 10.1681/ASN.2020121753
   PubMed Web of Science ®Google Scholar
• Mujtaba M, Fridell J, Sharfuddin A, et al. BK virus nephropathy in simultaneous pancreas kidney transplant: a potentially preventable cause of kidney allograft loss. Clin Transplant. 2012;26(2):E87–E93. doi: 10.1111/j.1399-0012.2012.01599.x
   PubMed Web of Science ®Google Scholar
• Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus–associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation. 2007;84(1):83–88. doi: 10.1097/01.tp.0000268524.27506.39
   PubMed Web of Science ®Google Scholar
• Elfadawy N, Flechner SM, Liu X, et al. CMV Viremia is associated with a decreased incidence of BKV reactivation after kidney and kidney-pancreas transplantation. Transplantation. 2013;96(12):1097–1103. doi: 10.1097/TP.0b013e3182a6890d
   PubMed Web of Science ®Google Scholar
• Elfadawy N, Flechner SM, Liu X, et al. The impact of surveillance and rapid reduction in immunosuppression to control BK virus-related graft injury in kidney transplantation. Transplant Int. 2013;26(8):822–832. doi: 10.1111/tri.12134
   PubMed Web of Science ®Google Scholar
• Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor–based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol. 2017;12(8):1321–1336. doi: 10.2215/CJN.13221216
   PubMed Web of Science ®Google Scholar
• Cantarovich D, Giral-Classe M, Hourmant M, et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation. 2000;69(7):1505–1508. doi: 10.1097/00007890-200004150-00051
   PubMed Web of Science ®Google Scholar
• Aoun M, Eschewege P, Hamoudi Y, et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol Dial Transplant. 2007;22(3):899–905. doi: 10.1093/ndt/gfl660
   PubMed Web of Science ®Google Scholar
• Fridell JA, Agarwal A, Powelson JA, et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation. 2006;82(3):389–392. doi: 10.1097/01.tp.0000228904.01482.88
   PubMed Web of Science ®Google Scholar
• Vessal G, Wiland AM, Philosophe B, et al. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clin Transplant. 2007;21(4):491–497. doi: 10.1111/j.1399-0012.2007.00675.x
   PubMed Web of Science ®Google Scholar
• Gallon LG, Winoto J, Chhabra D, et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation. 2007;83(10):1324–1329. doi: 10.1097/01.tp.0000264189.58324.91
   PubMed Web of Science ®Google Scholar
• Gruessner RW, Kandaswamy R, Humar A, et al. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation. 2005;79(9):1184–1189. doi: 10.1097/01.TP.0000161221.17627.8A
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction – long-term results. Am J Transplant. 2006;6(2):331–339. doi: 10.1111/j.1600-6143.2005.01166.x
   PubMed Web of Science ®Google Scholar
• Muthusamy AS, Vaidya AC, Sinha S, et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant. 2008;8(10):2126–2131. doi: 10.1111/j.1600-6143.2008.02373.x
   PubMed Web of Science ®Google Scholar
• Reddy KS, Devarapalli Y, Mazur M, et al. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Transplant Proc. 2010;42(6):2006–2008. doi: 10.1016/j.transproceed.2010.05.090
   PubMed Web of Science ®Google Scholar
• Uemura T, Ramprasad V, Matsushima K, et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. Transplantation. 2011;92(6):678–685. doi: 10.1097/TP.0b013e31822b58be
   PubMed Web of Science ®Google Scholar
• Rajab A, Pelletier RP, Ferguson RM, et al. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients. Transplantation. 2007;84(9):1131–1137. doi: 10.1097/01.tp.0000287117.98785.54
   PubMed Web of Science ®Google Scholar
• Tanchanco R, Krishnamurthi V, Winans C, et al. Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreas-kidney transplantation. Transplant Proc. 2008;40(5):1551–1554. doi: 10.1016/j.transproceed.2008.03.081
   PubMed Web of Science ®Google Scholar
• Cantarovich D, Karam G, Hourmant M, et al. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation. Am J Transplant. 2005;5(6):1332–1338. doi: 10.1111/j.1600-6143.2005.00816.x
   PubMed Web of Science ®Google Scholar
• Malheiro J, Martins L, Fonseca I, et al. Steroid withdrawal in simultaneous pancreas-kidney transplantation: a 7-year report. Transplant Proc. 2009;41(3):909–912. doi: 10.1016/j.transproceed.2009.03.036
   PubMed Web of Science ®Google Scholar
• Boggi U, Vistoli F, Andres A, et al. First world consensus conference on pancreas transplantation: part II - recommendations. Am J Transplant. 2021;21(Suppl 3):17–59.
   PubMedGoogle Scholar
• Montero N, Webster AC, Royuela A, et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev. 2014;(9):CD007669. doi:10.1002/14651858.CD007669.pub2
   PubMed Web of Science ®Google Scholar
• Trapecar M, Wogram E, Svoboda D, et al. Human physiomimetic model integrating microphysiological systems of the gut, liver, and brain for studies of neurodegenerative diseases. Sci Adv. 2021;7(5). doi: 10.1126/sciadv.abd1707
   PubMed Web of Science ®Google Scholar
• Alshamsan A, Binkhathlan Z, Kalam MA, et al. Mitigation of tacrolimus-associated nephrotoxicity by PLGA nanoparticulate delivery following multiple dosing to mice while maintaining its immunosuppressive activity. Sci Rep. 2020;10(1):6675. doi: 10.1038/s41598-020-63767-1
   PubMed Web of Science ®Google Scholar
• Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478. doi: 10.3389/fgene.2019.00478
   PubMed Web of Science ®Google Scholar
• Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990–999. doi: 10.1016/j.kint.2022.06.013
   PubMed Web of Science ®Google Scholar
• de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974–989. doi: 10.1016/j.kint.2022.08.012
   PubMed Web of Science ®Google Scholar
• Baigent C, Emberson J, Haynes R. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–1801. doi: 10.1016/S0140-6736(22)02074-8
   PubMed Web of Science ®Google Scholar
• Lim JH, Kwon S, Jeon Y, et al. The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation. 2022;106(9):e404–e412. doi: 10.1097/TP.0000000000004228
   PubMedGoogle Scholar
• Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (Sglt2i) in kidney transplant recipients: what is the evidence? Ther Adv Endocrinol Metab. 2022;13:20420188221090001.
   Web of Science ®Google Scholar
• Boeder S, Edelman SV. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. Diab Obes Metab. 2019;21 Suppl 2(S2):62–77. doi: 10.1111/dom.13749
   PubMedGoogle Scholar